Artivion Inc
$ 37.39
-2.45%
23 Feb - close price
- Market Cap 1,833,822,000 USD
- Current Price $ 37.39
- High / Low $ 38.32 / 37.13
- Stock P/E 182.52
- Book Value 9.37
- EPS 0.21
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 48.25
- 52 Week Low 21.97
About
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Analyst Target Price
$51.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-13 | 2024-11-07 | 2024-08-08 | 2024-05-06 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.17 | 0.16 | 0.03 | -0.012 | -0.3936 | -0.05 | -0.05 | 0.06 | -0.1 | -0.24 | -0.07 | -0.33 |
| Estimated EPS | 0.0583 | 0.03 | -0.0033 | 0.045 | 0.0375 | -0.06 | -0.02 | -0.09 | -0.1 | -0.06 | -0.08 | -0.14 |
| Surprise | 0.1117 | 0.13 | 0.0333 | -0.057 | -0.4311 | 0.01 | -0.03 | 0.15 | 0 | -0.18 | 0.01 | -0.19 |
| Surprise Percentage | 191.5952% | 433.3333% | 1009.0909% | -126.6667% | -1149.6% | 16.6667% | -150% | 166.6667% | 0% | -300% | 12.5% | -135.7143% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.042 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.0275 | $0.0275 | $0.0275 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AORT
2026-02-24 02:52:53
Artivion (AORT) has returned to profitability in Q4 2025 and the full year, reporting increased revenue and net income, reversing prior-year losses. This turnaround is largely attributed to strong demand for their stent grafts and On-X mechanical heart valves, supported by new clinical data. While operational risks related to cybersecurity and tissue processing persist, the positive financial results and product demand are reshaping the company's investment narrative and improving confidence in its future growth.
2026-02-21 20:27:54
The global hemostats market is projected to grow from USD 4.75 billion in 2023 to USD 7.94 billion by 2030, exhibiting a CAGR of 7.6%. This growth is driven by the increasing prevalence of chronic diseases and surgical procedures, as well as innovations and regulatory approvals for new products. North America currently dominates the market, with Europe following, while significant market contenders are emerging through strategic mergers and acquisitions.
2026-02-18 12:27:41
Public Sector Pension Investment Board increased its stake in Artivion, Inc. (NYSE:AORT) by 23.7% in the third quarter, now owning 161,970 shares valued at approximately $6.86 million, representing 0.34% of the company. Other institutional investors also adjusted their positions, with overall institutional ownership at 86.37%. Artivion recently reported an EPS of $0.17, beating estimates, and revenue growth of 19.2% year-over-year to $118.3 million, while analysts maintain a "Moderate Buy" rating with a consensus target price of $48.97.
2026-02-14 00:28:30
Artivion Inc. (AORT) reported robust Q4 and full-year 2025 results, demonstrating strong revenue growth, improved EBITDA margins, and significant deleveraging. While challenges like a cyber incident, tissue softness, and increased CapEx/R&D persist, management expressed confidence in achieving 2026 targets through growth in stent grafts and On-X valves, and ongoing clinical and regulatory advancements. The company projects continued double-digit revenue growth and margin expansion into 2026.
2026-02-13 19:57:11
Artivion (NYSE:AORT) shares dropped 6.5% during trading, falling below key moving averages, despite beating quarterly EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus, but insider selling and a negative net margin raise concerns. The article highlights these mixed signals and briefly describes Artivion as a global medical technology company specializing in implantable tissue products and surgical devices for cardiac and vascular surgery.
2026-02-13 19:57:11
Canaccord Genuity has reaffirmed its "Buy" rating for Artivion (AORT) but has reduced the stock's price target to $48.00 from $51.00, a 5.88% decrease. Despite the lower target from Canaccord Genuity, the average one-year price target from 7 analysts is $51.71, suggesting a 46.21% upside from the current price. However, GuruFocus estimates a fair value of $26.42, indicating a potential downside of 25.3% for the stock.
